Suppression of hemostatic system activation by oral anticoagulants in the blood of patients with thrombotic diatheses.
RIAs for hemostatic system activation were employed to study patients who were anticoagulated with warfarin. The mean prothrombin fragment F1 + 2 concentration in stably anticoagulated individuals without an inherited thrombotic diathesis (mean prothrombin time [PT] ratio [PT of patient/PT of normal plasma pool] = 1.74) was 0.231 nM as compared with a mean plasma F1 + 2 level of 1.68 nM for a nonanticoagulated control group (P less than 0.0001). The initiation of oral anticoagulants in two subjects who did not exhibit protein C deficiency led to a paradoxical increase in F1 + 2 levels during the first day of therapy. We have also shown that a relatively low intensity regimen of warfarin (PT ratio less than 1.2) may reduce elevated concentrations of F1 + 2 into the normal range in patients with a history of recurrent thromboembolism. The mean F1 + 2 level in antithrombin-deficient individuals on warfarin was significantly elevated (mean = 0.714 nM) as compared with that in anticoagulated subjects with protein C deficiency (mean = 0.205 nM) or in those without an inherited thrombotic disorder (P less than 0.01) at equivalent levels of intensity of oral anticoagulation. We therefore conclude that the effect of warfarin on hemostatic system activation is modulated by the endogenous heparan sulfate-antithrombin mechanism.
Conway
E M
EM
Charles A. Dana Research Institute, Boston, Massachusetts.
Bauer
K A
KA
Barzegar
S
S
Rosenberg
R D
RD
D000284:Administration, Oral; D000328:Adult; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use*; D003864:Depression, Chemical; D005344:Fibrinopeptide A / Q000032:analysis; D006487:Hemostasis / Q000187:drug effects*; D006801:Humans; D008875:Middle Aged; D009842:Oligopeptides / Q000032:analysis; D010446:Peptide Fragments / Q000032:analysis; D011516:Prothrombin / Q000032:analysis; D013923:Thromboembolism / Q000517:prevention & control*; D014859:Warfarin / Q000008:administration & dosage / Q000627:therapeutic use
D000925:Anticoagulants; D009842:Oligopeptides; D010446:Peptide Fragments; C047135:protein C activator peptide; C045879:prothrombin fragment 1.2; D005344:Fibrinopeptide A; D014859:Warfarin; D011516:Prothrombin